Jupiter Neurosciences doses first Parkinson's patient in JOTROL Phase 2a trial, testing whether enhanced resveratrol achieves therapeutic brain concentrations.

Remibrutinib reduces relapse rates versus teriflunomide in Phase 3 MS trials REMODEL-1 and REMODEL-2, with results presented at MSToronto2026.

FDA approves Rhapsido (remibrutinib) for symptomatic dermographism, the first prescription treatment for adults with the condition inadequately controlled by...

Rovia grew a site network in places where sponsors needed patient access. Now sponsors are coming to him.

FDA's September 2026 adcomm recruitment push signals shifts in protocol feedback loops that sponsor clinops and sites can't afford...

JAMA's 2026 editorial exposes how "pragmatic trial" has been stretched beyond recognition, threatening regulatory credibility and real-world evidence quality.

AI deployment in clinical studies requires validation framework and governance structure to address compliance gaps and enable safe implementation.

CRScube and Mednet demonstrate integration-free EHR-to-EDC tool designed to reduce manual transcription errors and streamline clinical data capture.

Oculis to present licaminlimab data at AAO 2026 following year-end PREDICT-1 readout in genotype-selected dry eye patients.

Rezdiffra shows consistent efficacy across common MASH genetic risk variants in Phase 3 analysis, addressing prescribing concerns for high-risk...